Reyataz Labeling Update Cautions Against Use With PPIs
This article was originally published in The Pink Sheet Daily
Bristol-Myers Squibb’s protease inhibitor adds a study showing Prilosec substantially reduced plasma concentrations.
You may also be interested in...
GSK/Vertex’s post-marketing study found that proton pump inhibitor use does not lessen the protease inhibitor’s efficacy.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The US FDA shaved months from review of Gilead’s Veklury (remdesivir) for COVID-19 with post-approval commitments for multiple stability studies. The Pink Sheet takes a deep dive look at discussions within the agency and with the sponsor.